Advertisement

Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px
Collaboration › Details

TATAA Biocenter–UST Corp: DNA sequencing technology, 202301– collab TATAA to use UST’s TELL-seq technology for sequencing services

 

Period Period 2023-01-11
Organisations Partner, 1st TATAA Biocenter AB
  Partner, 2nd Universal Sequencing Technology Corporation (d/b/a UST Corporation)
Products Product TELL-Seq Linked Read technology
  Product 2 DNA sequencing service
     

TATAA Biocenter AB. (1/11/23). "Press Release: TATAA Biocenter Partners with Universal Sequencing Technology Corporation to Offer “Linked Long Read” Sequencing Services".

TATAA Biocenter has partnered with Universal Sequencing Technology Corporation (UST) to offer full-service solutions for Long Read Sequencing Applications using UST TELL-Seq Linked Read technology.

TATAA Biocenter was founded in 2001 and is a leading provider of molecular services to the Advanced Therapies and Medical products (ATMP) industries in Europe and to the Cell and Gene Therapy industry in the United States.

UST’s TELL-Seq technology, a transposase-based patent-pending linked-read library technology, enables short read 2nd generation NGS platforms, such as Illumina sequencers, to produce super long-range sequencing results (averaging linked-read molecule length greater than 40kb, up to and exceeding 200kb). A sequencing-ready library can be prepared in a PCR tube in ~3 hours with a simple workflow and basic lab equipment, which is simple, fast, and cost-effective. A unique feature of UST TELL-Seq is that it only requires ultra-low DNA input, 3-5ng for the human genome and 0.1-0.5ng for microbial genomes and target sequencing panels.

Dr. Aaron U. Levy, GM & Chief Commercial Officer of UST, who recently visited the TATAA Biocenter facility in Gothenburg, stated that he was impressed with the laboratory’s setup, corporate culture, professionalism, and up-to-code superb sequencing services. Levy added that “TELL-Seq library technology is compatible with the range of Illumina sequencing platforms from benchtop like MiniSeq™ up to high-throughput NovaSeq™ 6000. The collaboration between UST and TATAA, based on the growing need for long-read results with very accurate short-read Illumina sequencers is speeding up the adoption of UST’s super long-range TELL-Seq NGS library products among Illumina users in the US and all over the world.”

With UST TELL-Seq library preparation kits and an Illumina sequencer, one can do de novo sequencing of microbial, animal, plant, and insect genomes, metagenomics, human genome phasing, and structural variation detection.

Mikael Kubista, the founder and CEO of TATAA Biocenter, stated, “The innovative TELL-Seq Linked-Read Technology for long-read sequencing is a most welcome complement to our service offerings. Our customers and sponsors will now gain additional advantages over their competitors through our broad range of qualified molecular services.”


Contact for more info:
Martin Cooke, TATAA Biocenter, Marketing & Comms Specialist.
Emaii: martin.cooke@tataa.com

 

ABOUT TATAA BIOCENTER

TATAA Biocenter is a leading provider of molecular services to the Advanced Therapies and Medical products (ATMP) industry in Europe and to the Cell and Gene Therapy industry in the United States. With ISO 17025 accreditation and Good Laboratory and Clinical Practices

(GLP/GCP) ready facility TATAA is perfectly positioned to support the pharmaceutical industry with biomarker profiling, including genomics, transcriptomics, and proteomics with traditional qPCR, dPCR, and NGS methods, as well as proprietary methods.


ABOUT UNIVERSAL SEQUENCING TECHNOLOGY CORPORATION

Universal Sequencing Technology Corporation (UST), a Boston and San Diego-based NGS biotechnology company, was established by a group of NGS veterans. UST is dedicated to developing the most advanced DNA sequencing technologies and has filed more than 20 provisional patent applications covering linked read NGS library preparation, single-cell sequencing, and groundbreaking 3rd generation DNA sequencing technologies. UST is poised to lead the next wave of DNA sequencing innovations.

   
Record changed: 2023-01-29

Advertisement

Picture EBD Group BIO-Europe 2023 Munich BEU23 650x200px

More documents for TATAA Biocenter AB


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture BIO.NRW Greener Manufacutring Show 2023 Köln 650x300px




» top